Role of Imbruvica (ibrutinib) ...Dr. Wierda - CLL Support
Role of Imbruvica (ibrutinib) ...Dr. Wierda
Good to know there is work toward quality-of-life in both side-effects and financial/long-term usage of Ibrutinib.
The current path of these high priced cancer drugs is simply not sustainable for the long term. As they become more widely dispensed, the net overall financial drain on our healthcare coverage systems will force significant changes in the pricing model.
This article highlights the rapid rise in financial burden created by the newer oral agents.
Hope, we can hear also more specialists like some from Europe, to discuss the role of Ibrutinib, as Dr. Wierda is one of the main Advokat for the Pharma companies producing and distributing Ibruvica. Although I appriciate the work of him, I sometimes start thinking, whether advocats are accelerating drugs. We could learn this during the ABBvie/Janssen/Pharmacyclists sponsored part of iwCLL 2017.
I sure would like to be in a reduced dose trial although I can't say I've had any issues that were negative taking 420 a day.